Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Embecta Corp
NASDAQ EMBC
Data sourced from
and
and
Embecta Corp Selling, General, and Administrative Expenses (SG&A) 3 year CAGR for the quarter ending March 31, 2024: 18.26%
Embecta Corp Selling, General, and Administrative Expenses (SG&A) 3 year CAGR is 18.26% for the quarter ending March 31, 2024. Selling, General, and Administrative Expenses (SG&A) consit of the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Embecta Corp Selling, General, and Administrative Expenses (SG&A) for the quarter ending March 31, 2023 was USD 112.10 M, a 50.87% change year over year.
-
Embecta Corp Selling, General, and Administrative Expenses (SG&A) for the quarter ending March 31, 2022 was USD 74.30 M, a 33.15% change year over year.
-
Embecta Corp Selling, General, and Administrative Expenses (SG&A) for the quarter ending March 31, 2021 was USD 55.80 M.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: EMBC
| CEO | Mr. Devdatt Kurdikar |
| IPO Date | April 1, 2022 |
| Location | United States |
| Headquarters | 300 Kimball Drive, Parsippany, NJ, United States, 07054 |
| Employees | 2,200 |
| Sector | Healthcare |
| Industry | Medical instruments & supplies |
Description
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Key trends
Similar companies
AngioDynamics Inc
NA
NA
Akoya Biosciences Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email